Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 16/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | UBE2N | P61088 | 1/20 | 0.31 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17508421 | 0.87 | TRPC5 (0.41) | TRPC5MEN1TSHRKMT2AMAPT | |
| SCHEMBL17508393 | 0.77 | TRPC5 (0.43) | TRPC5MAPTKCNH2TRPC4 | |
| SCHEMBL20525494 | 0.70 | TRPC5 (0.41) | TRPC5MEN1KMT2AMAPT | |
| SCHEMBL17508422 | 0.70 | TRPC5 (0.42) | TRPC5 | |
| SCHEMBL17508801 | 0.69 | TRPC5 (0.76) | TRPC5MEN1TSHRKMT2AMAPT | |
| SCHEMBL17538648 | 0.66 | TRPC5 (0.49) | TRPC5MEN1TSHRKMT2AUBE2N | |
| SCHEMBL17509556 | 0.66 | TRPC5 (0.49) | TRPC5MEN1TSHRKMT2AUBE2N | |
| SCHEMBL17546479 | 0.66 | TRPC5 (0.44) | TRPC5KCNH2TRPC4 | |
| SCHEMBL17509555 | 0.64 | TRPC5 (0.47) | TRPC5MEN1TSHRKMT2AUBE2N | |
| SCHEMBL17509577 | 0.62 | TRPC5 (0.46) | TRPC5MEN1TSHRKMT2AUBE2N |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180337-B1 | PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES INC (US) | 2018-10-10 | — | — | EP | disclosed |
| EP-3180337-A1 | PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | Hydra Biosciences, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-9440973-B2 | Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440973-B2 | Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9440973-B2 | Pyrido[3,4-d]pyrimidine-2,4(1H,3H)-dione derivatives | HYDRA BIOSCIENCES, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| WO-2016023825-A1 | PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016023825-A1 | PYRIDO[3,4-D]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20160039815-A1 | PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160039815-A1 | PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160039815-A1 | PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | HYDRA BIOSCIENCES, INC. | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039815-A1 | PYRIDO[3,4-d]PYRIMIDINE-2,4(1H,3H)-DIONE DERIVATIVES | TRPC5, P2RX5, HTR5A | TRPC5 1/4885MEN1 2937/4885TSHR 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.